BioCryst Pharmaceuticals (NASDAQ:BCRX) Lowered to “Hold” Rating by Wall Street Zen

Wall Street Zen lowered shares of BioCryst Pharmaceuticals (NASDAQ:BCRX) from a strong-buy rating to a hold rating in a report published on Saturday.

Several other research firms also recently weighed in on BCRX. Needham & Company LLC decreased their price objective on BioCryst Pharmaceuticals from $18.00 to $16.00 and set a “buy” rating for the company in a report on Wednesday. Citizens Jmp increased their price objective on BioCryst Pharmaceuticals from $25.00 to $28.00 and gave the company a “market outperform” rating in a report on Thursday. Weiss Ratings raised BioCryst Pharmaceuticals from a “sell (d-)” rating to a “hold (c)” rating in a report on Wednesday, March 4th. Wedbush decreased their price objective on BioCryst Pharmaceuticals from $22.00 to $21.00 and set an “outperform” rating for the company in a report on Thursday. Finally, Evercore began coverage on BioCryst Pharmaceuticals in a report on Wednesday, February 18th. They issued an “outperform” rating and a $17.00 price objective for the company. Nine investment analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $20.70.

BioCryst Pharmaceuticals Trading Down 3.1%

BCRX stock opened at $8.62 on Friday. The company has a market capitalization of $2.19 billion, a P/E ratio of -4.84 and a beta of 0.57. BioCryst Pharmaceuticals has a twelve month low of $6.00 and a twelve month high of $11.31. The business has a 50 day simple moving average of $9.08 and a 200-day simple moving average of $7.83.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported ($2.98) earnings per share for the quarter, missing the consensus estimate of $0.06 by ($3.04). The firm had revenue of $156.41 million during the quarter, compared to analyst estimates of $151.12 million. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. BioCryst Pharmaceuticals’s revenue was up 7.5% compared to the same quarter last year. During the same period in the previous year, the company posted $0.20 earnings per share. Research analysts predict that BioCryst Pharmaceuticals will post 0.31 EPS for the current fiscal year.

Insider Activity at BioCryst Pharmaceuticals

In other news, insider Alane P. Barnes sold 150,000 shares of the company’s stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $9.15, for a total transaction of $1,372,500.00. Following the completion of the sale, the insider owned 400,703 shares in the company, valued at $3,666,432.45. This represents a 27.24% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 5.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On BioCryst Pharmaceuticals

Several large investors have recently modified their holdings of BCRX. Larson Financial Group LLC raised its stake in shares of BioCryst Pharmaceuticals by 1,188.0% during the fourth quarter. Larson Financial Group LLC now owns 3,542 shares of the biotechnology company’s stock worth $28,000 after purchasing an additional 3,267 shares during the last quarter. Focus Partners Wealth purchased a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $77,000. Farther Finance Advisors LLC raised its stake in shares of BioCryst Pharmaceuticals by 326.8% during the third quarter. Farther Finance Advisors LLC now owns 10,590 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 8,109 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. raised its stake in shares of BioCryst Pharmaceuticals by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,231 shares of the biotechnology company’s stock worth $80,000 after purchasing an additional 2,115 shares during the last quarter. Finally, Vestmark Advisory Solutions Inc. purchased a new stake in shares of BioCryst Pharmaceuticals during the third quarter worth approximately $81,000. Hedge funds and other institutional investors own 85.88% of the company’s stock.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc is a clinical‐stage biotechnology company headquartered in Durham, North Carolina, that focuses on the discovery and development of novel, oral small‐molecule medicines for rare and serious diseases. Since its founding in 1986, the company has leveraged structure‐based drug design to advance a pipeline of targeted therapeutics designed to address underlying disease mechanisms rather than just treat symptoms.

The company’s first commercial product, Orladeyo (berotralstat), is an oral kallikrein inhibitor approved for the prophylactic treatment of hereditary angioedema (HAE) in both the United States and Europe.